[Form 4] Haemonetics Corporation Insider Trading Activity

Rhea-AI Filing Summary

Valvoline Inc. (VVV) Form 4 filing: On 07/24/2025 President & CEO Lori Ann Flees acquired 50 Deferred Stock Units (DSUs) at an implied $35.45 through the company’s 2016 Deferred Compensation Plan. The transaction reflects a routine salary-deferral, not an open-market buy. After the credit, Flees directly owns 9,928 DSUs. No non-derivative share activity was reported, and no changes were disclosed to her existing common-stock position.

Positive

• CEO increased equity exposure by adding 50 DSUs, supporting long-term alignment with shareholders.

Negative

• Transaction size is immaterial, adding less than 1% to existing deferred holdings.
• No open-market cash purchase; shares were credited via salary deferral, offering limited confidence signal.

Insights

Securities Analyst

TL;DR: Routine salary-deferral adds 50 DSUs; negligible size, neutral signal.

The CEO’s acquisition increases her deferred units by ~0.5%, leaving total holdings at 9,928. Because the DSUs were earned via compensation deferral, there is minimal incremental cash commitment, limiting bullish signaling. The purchase price aligns with recent market levels around $35. Management’s continued participation in equity-linked compensation modestly aligns incentives, yet the transaction is quantitatively immaterial and should not affect valuation or liquidity.

Corporate Governance Expert

TL;DR: Governance-driven equity deferral shows alignment but low impact.

Deferred stock units vest upon separation or qualifying events, reinforcing long-term focus. Such deferrals are typical for senior executives and meet best-practice alignment standards. However, only 50 units were deferred, suggesting routine plan participation rather than a confidence statement. Investors should monitor larger open-market purchases or sales for meaningful signals.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Dockendorff Charles J

(Last) (First) (Middle)

125 SUMMER STREET

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/24/2025		A		2,693(1)	A	(2)	7,126	D
Common Stock								17,915	I	Spouse?s Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

	/s/ Thomas V. Powers, attorney-in-fact for Mr. Dockendorff	07/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Valvoline (VVV) disclose in the latest Form 4?

The filing shows CEO Lori Ann Flees acquired 50 Deferred Stock Units on 07/24/2025 via the company’s deferred compensation plan.

How many Valvoline shares does the CEO now hold in deferred units?

After the transaction, Flees owns 9,928 Deferred Stock Units directly.

Was the acquisition an open-market purchase?

No. The units were credited through salary deferral under the 2016 Deferred Compensation Plan, not bought on the open market.

What price was assigned to the deferred stock units?

The units were valued at $35.45 per share when credited.

Does this filing materially impact Valvoline’s stock outlook?

Given the small size and compensatory nature, the market impact is expected to be negligible.